Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients

doi:10.5306/wjco.v9.i7.140

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6935)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

462

WORD

309

HTML

3370

Figures (1-3)

276

Tables (1-4)

282

Sum=4699

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

907

Download

1329

Sum=2236

Nov 10, 2018 (publication date) through Dec 30, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Nov 10, 2018; 9(7): 140-147
Published online Nov 10, 2018. doi: 10.5306/wjco.v9.i7.140

Table 2 Baseline characteristics of the study population n (%)

Characteristic	Total, n = 1501
Age in yr	58.4 (10.8)
Males	1236 (82.3)
Smokers	1155 (76.9)
Body mass index in kg/m²	20.2 (4.2)
Histopathology
NSCLC: Squamous	553 (36.8)
NSCLC: Adeno	514 (34.2)
NSCLC: Undifferentiated	87 (5.8)
NSCLC: Other	42 (2.8)
SCLC	305 (20.3)
NSCLC/SCLC stage¹
I and II	44 (2.9)
IIIA	193 (12.9)
IIIB	426 (28.4)
IV	767 (51.1)
SCLC stage
Limited disease	145 (9.7)
Extensive disease	160 (10.7)
Baseline performance status
KPS	77.6 (14.4)
ECOG PS	1.5 (1)

¹Total does not add up to 1501 as TNM staging was available for only some of the patients with SCLC. All values are mean (standard deviation) unless otherwise specified. ECOG PS: Eastern Cooperative Oncology Group performance status; KPS: Karnofsky performance status; NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer.

Citation: Prasad KT, Kaur H, Muthu V, Aggarwal AN, Behera D, Singh N. Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients. World J Clin Oncol 2018; 9(7): 140-147
URL: https://www.wjgnet.com/2218-4333/full/v9/i7/140.htm
DOI: https://dx.doi.org/10.5306/wjco.v9.i7.140